ERAP1 and neoplasm: Previously, we have demonstrated that genetic and pharmacological inhibition of ERAP1 on murine and human tumor cell lines perturbs their ability to engage several classes of inhibitory receptors by their ligands, including Ly49C/I and killer cell Ig-like receptors (KIR), respectively, leading to NK cell killing (27, 28).